The global circulating tumor cells market size is expected to reach USD 18.3 billion by 2027, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 11.7% from 2021 to 2027. Many potential applications of CTCs in pre-diagnosis, pretreatment, and intra- and post-treatment provide lucrative growth opportunities to players involved in the development of CTC enrichment and isolation products Research organizations are engaged in endeavors aimed at developing CTC-based tests to improve cancer diagnosis in terms of efficiency and speed.
Furthermore, the growing demand for minimally invasive diagnostic procedures is anticipated to propel investments by key stakeholders in this area. CTC-based liquid biopsy tests lead to limited trauma and enable rapid recovery owing to their non-invasive nature. Moreover, it enables minimal invasive screening of tumors before opting for complex surgical procedures, such as radiotherapy, chemotherapy, and surgical removal of tumors, thus positively impacting the adoption.
The limited applicability of these cells in rare cancers has hampered the revenue growth up to a certain extent. For instance, there is negligible evidence for the characterization of CTCs for sarcoma. Conversely, several methods are being investigated for the isolation of these cells, such as methods based on epithelial antigen-targeted antibodies, which are anticipated to help overcome these challenges in the coming years.
Request a free sample copy or view report summary: Circulating Tumor Cells Market Report
The CTC detection and enrichment methods accounted for the largest revenue share owing to the presence of wide availability of products for CTC enrichment and isolation
Moreover, high penetration in terms of usage of products offered under this segment has driven the segment share
The growing application of nanomaterials in cancer management is anticipated to drive revenue for direct detection methods in the coming years
The devices and systems segment dominated the market in terms of revenue share in 2020 over its counterpart segments including kits and reagents and blood collection tubes
The presence of high-throughput automated systems coupled with the availability of a substantial number of systems to carry out detection of tumor cells has contributed to a large revenue share
CTC analysis has major applications in research settings, including investigational research, drug developments, and biomarker studies. This has resulted in a segment’s large revenue share
Currently, whole blood specimens are the key source of CTCs, thus accounting for the largest share in 2020
Low use of bone marrow-derived cells in clinical settings has contributed to a smaller revenue share of this segment
Other sources include CSF, spinal fluids, urine, and pleural effusion
Easy availability of biological specimens, such as urine, is likely to accelerate adoption under this segment
The market is fragmented in nature with the presence of well-established players, along with medium to small-sized players
Grand View Research has segmented the global Circulating Tumor Cells market on the basis of technology, application, product, specimen, and region:
CTCs Technology Outlook (Revenue, USD Million, 2018 - 2027)
CTC Detection & Enrichment Methods
Size-based Separation (Label-free)
Density-based Separation (Label-free)
Combined Methods (Label-free)
CTC Direct Detection Methods
CTCs Application Outlook (Revenue, USD Million, 2018 - 2027)
Clinical/ Liquid Biopsy
Screening and Monitoring
Cancer Stem Cell & Tumorogenesis Research
CTCs Product Outlook (Revenue, USD Million, 2018 - 2027)
Kits & Reagents
Blood Collection Tubes
Devices or Systems
CTCs Specimen Outlook (Revenue, USD Million, 2018 - 2027)
Other Body Fluids
CTCs Regional Outlook (Revenue, USD Million, 2018 - 2027)
Middle East & Africa
List of Key Players of Circulating Tumor Cells (CTCs) Market
Precision for Medicine
Fluxion Biosciences, Inc.
Greiner Bio One International GmbH
Canopus Bioscience Ltd.
Creativ MicroTech, Inc.
LungLife AI, Inc.
Menarini Silicon Biosystems
LineaRx, Inc. (Vitatex, Inc.)
STEMCELL Technologies, Inc.
This report has a service guarantee. We stand by our report quality.
Your transaction & personal information is safe and secure.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
Avail customized purchase options to meet your research needs:
"The quality of research they have done for us has been excellent..."